UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Results of clinical trials conducted in the United Kingdom have shown that a nitric oxide nasal spray (NONS, SaNOtize) is both a safe and effective antiviral treatment to prevent COVID-19 transmission and symptom duration, as well as reduce symptom severity and damage in those already infected, according to the study authors.

During the randomized, double-blind, placebo-controlled phase 2 trial, the investigators assessed 79 patients with confirmed COVID-19 who were given the spray early following diagnosis. The results following treatment demonstrated that the spray significantly reduced the level of SARS-CoV-2, even in patients with high viral loads, according to the study.

"NONS destroys the virus, blocks entry into and halts viral replication within the nasal cavity," SaNOtize says. "This is significant because viral load has been linked to infectivity and poor outcomes," Chris Miller, PhD, RT says. In the first 24 hours following treatment with the spray, investigators observed that the average viral log reduction was 1.362, which is a decline of approximately 95%. After 72 hours following treatment, the viral load decreased by more than 99%.

Additionally, the majority of patients included in the study were found to be infected with the UK variant of SARS-CoV-2, which has been a variant of concern in terms of treatments. Following treatment with the nasal spray, patients had no adverse events during the UK trial, which corresponds with the results from earlier Canadian clinical trials that assessed results from more than 7000 self-administered treatments of the nasal spray by patients.

Currently, the spray is the only novel therapeutic treatment that has demonstrated a significant reduction in viral load in humans that is not a monoclonal antibody treatment. This is an asset because monoclonal antibody treatments are not only very specific but also expensive and need intravenous administration in a clinical setting. The novel spray does not require in-clinic administration and can be self-administered by patients, while also being more affordable.

Additionally, the pharmacology, toxicity, and safety data for NO use in humans has been known for decades, which has allowed it to be a safe treatment method for use in newborn babies as well as adults. Specifically, the NO molecule used in the novel spray is identical to the molecule that has been used to treat persistent pulmonary hypertension in newborn babies.

Source:
https://www.businesswire.com/news/home/20210315005197/en
Dr. T●●●●z H●●●●●●i and 18 others like this20 shares
Like
Comment
Share
Dr. R●●a L●●●y
Dr. R●●a L●●●y Hepatobiliary Surgery
I was diagnosed with multiple sclerosis (MS). My vision was blurred for three months. I had closed my fingers in my front door without realizing it. I knew then something was wrong. I called my primary doctor who examined me and then sent me to the hospital. An MRI was performed and I was diagnosed with MS. I have been on World Herbs Clinic, MS HERBAL FORMULA for two month plus now, all my symptoms has decline completely, i feel normal again, but i have few weeks left completing the treatment.... Read more
Apr 14, 2021Like1